The Importance of Being Grade 3: A Plea for a Three-tier Hybrid Classification System for Grade in Primary Non–muscle-invasive Bladder Cancer
Grade is an important determinant of progression in non-muscle-invasive bladder cancer. Although the World Health Organization (WHO) 2004/2016 grading system is recommended, other systems such as WHO1973 and WHO1999 are still widely used. Recently, a hybrid (three-tier) system was proposed, separating WHO2004/2016 high grade (HG) into HG/grade 2 (G2) and HG/G3 while maintaining low grade. We assessed the prognostic performance of HG/G3 and HG/G2. Three independent cohorts with 9712 primary (first diagnosis) Ta-T1 bladder tumors were analyzed. Time to progression was analyzed with cumulative incidence functions and Cox regression models. Harrell's C-index was used to assess discrimination. Time to progression was significantly shorter for HG/G3 than for HG/G2 in multivariable analyses (cohort 1: hazard ratio [HR] = 1.92; cohort 2: HR = 2.51, and cohort 3: HR = 1.69). Corresponding progression risks at 5 yr were 18%, 20%, and 18% for HG/G3 versus 7.3%, 7.5%, and 9.3% for HG/G2, respectively. Cox models using hybrid grade performed better than models with WHO2004/2016 (all cohorts; p < 0.001). For the three cohorts, C-indices for WHO2004/2016 were 0.69, 0.62, and 0.75, while, for hybrid grade, C-indices were 0.74, 0.68, and 0.78, respectively. Subdividing the HG category into HG/G2 and HG/G3 stratifies time to progression and supports the recommendation to adopt the hybrid grading system for Ta/T1 bladder cancers.
Authors
- Matthew Trail (ORCID: https://orcid.org/0000-0003-0131-8064)
- María J. Ribal (ORCID: https://orcid.org/0000-0001-8142-5382)
- Lars Holmberg (ORCID: https://orcid.org/0000-0003-4417-7396)
- Luisa Padovani
- Richard Sylvester (ORCID: https://orcid.org/0000-0003-0529-862X)
- Irene Beijert (ORCID: https://orcid.org/0000-0002-0510-2300)
- David Hendry
- Paramananthan Mariappan (ORCID: https://orcid.org/0000-0001-8221-4640)
- Truls Gårdmark (ORCID: https://orcid.org/0000-0003-4610-0771)
- Fredrik Liedberg (ORCID: https://orcid.org/0000-0001-8193-0370)
- Paolo Gontero (ORCID: https://orcid.org/0000-0002-9714-6596)
- Oskar Hagberg (ORCID: https://orcid.org/0000-0001-5997-9813)
- Theodorus van der Kwast (ORCID: https://orcid.org/0000-0001-8640-5786)
- Éva Compérat (ORCID: https://orcid.org/0000-0001-8488-543X)
- Morgan Rouprêt (ORCID: https://orcid.org/0000-0001-8440-7075)
- Christel Häggström (ORCID: https://orcid.org/0000-0001-6808-4405)
- Imran Ahmad (ORCID: https://orcid.org/0000-0002-4404-1926)
- Roberta Garau
- Rami Hasan (ORCID: https://orcid.org/0000-0003-4667-0862)
- Allan Johnston
- Sami Hamid
- Marko Babjuk
- Maximilian Burger (ORCID: https://orcid.org/0009-0005-5013-9435)
- Bas W.G. van Rhijn
- B. Dreyer
Institutions
- Uppsala University (SE)
- University Health Network (CA)
- University of Toronto (CA)
- Lund University (SE)
- Western General Hospital (GB)
- University Hospital Ayr (GB)
- European Association of Urology (NL)
- Vienna General Hospital (AT)
- Ninewells Hospital (GB)
- Edinburgh Cancer Research (GB)
- Princess Margaret Cancer Centre (CA)
- Karolinska Institutet (SE)
- Sorbonne Université (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NL)
- Victoria Hospital (GB)
- Queen Elizabeth University Hospital (GB)
- Onco-Urologie Prédictive (FR)
- Umeå University (SE)
Publication Details
- Journal
- European Urology
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1016/j.eururo.2024.08.013
- Citations
- 9
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.15
Funders
- Univerzita Karlova v Praze
- Swedish Movement Disorder Society
- Scottish Government
- Bladder Cancer Canada
- Swedish Council of America
- Amsterdam University Medical Centers
- King's College London
- University of Glasgow
- Radboud Universiteit
- European Association of Urology
- Lunds Universitet
- Linköpings Universitet
- Karolinska Institutet
- Umeå Universitet
- Universität Regensburg
- Sahlgrenska Universitetssjukhuset
- Göteborgs Universitet
- Radboud Universitair Medisch Centrum
- Uppsala Universitet
- Karl-Franzens-Universität Graz
- Medizinische Universität Graz
- Skånes universitetssjukhus
- Universitat Autònoma de Barcelona
- Sorbonne Université
- Sahlgrenska Akademin
- Faculty of Medicine and Health, University of Sydney